
Clinical-stage biotech company Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) reported its financial results and updated on its programs pipeline of the third quarter ended September 30, 2022.
For the period, total cash was equivalent to $154.5 million -compared to $133.5 million as of December 31, 2021. Net cash used in operating activities was $37.3 million for the nine months ended September 30, 2022, compared to $38.0 million for the same period in 2021.